A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6

P Iversen; T L J Tammela; S Vaage; O Lukkarinen; P Lodding; T Bull-Njaa; J Viitanen; P Hoisaeter; P Lundmo; F Rasmussen; J-E Johansson; B-E Persson; K Carroll; Scandinavian Prostatic Cancer Group (SPCG)

A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6

P Iversen, T L J Tammela, S Vaage, O Lukkarinen, P Lodding, T Bull-Njaa, J Viitanen, P Hoisaeter, P Lundmo, F Rasmussen, J-E Johansson, B-E Persson, K Carroll, Scandinavian Prostatic Cancer Group (SPCG)

51 Citationer (Scopus)

Abstract

To assess the efficacy and tolerability of bicalutamide 150 mg ('Casodex'(1)) as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with early (T1b-T4, any N, M0) prostate cancer.

Originalsprog	Engelsk
Tidsskrift	European Urology
Vol/bind	42
Udgave nummer	3
Sider (fra-til)	204-11
Antal sider	8
ISSN	0302-2838
Status	Udgivet - 2002

Andre filer og links

Link to publication in Scopus

Fingeraftryk

Dyk ned i forskningsemnerne om 'A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Iversen, P., Tammela, T. L. J., Vaage, S., Lukkarinen, O., Lodding, P., Bull-Njaa, T., Viitanen, J., Hoisaeter, P., Lundmo, P., Rasmussen, F., Johansson, J.-E., Persson, B.-E., Carroll, K., & Scandinavian Prostatic Cancer Group (SPCG) (2002). A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. European Urology, 42(3), 204-11.

A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. / Iversen, P; Tammela, T L J; Vaage, S et al.
I: European Urology, Bind 42, Nr. 3, 2002, s. 204-11.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Iversen, P, Tammela, TLJ, Vaage, S, Lukkarinen, O, Lodding, P, Bull-Njaa, T, Viitanen, J, Hoisaeter, P, Lundmo, P, Rasmussen, F, Johansson, J-E, Persson, B-E, Carroll, K & Scandinavian Prostatic Cancer Group (SPCG) 2002, 'A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6', European Urology, bind 42, nr. 3, s. 204-11.

@article{a9bb7ddead154dcd8196e19a2ced7398,

title = "A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6",

abstract = "To assess the efficacy and tolerability of bicalutamide 150 mg ('Casodex'(1)) as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with early (T1b-T4, any N, M0) prostate cancer.",

keywords = "Aged, Aged, 80 and over, Anilides, Antineoplastic Agents, Chemotherapy, Adjuvant, Combined Modality Therapy, Double-Blind Method, Humans, Male, Middle Aged, Neoplasm Staging, Nitriles, Prostatic Neoplasms, Sexual Behavior, Survival Analysis, Time Factors, Tosyl Compounds",

author = "P Iversen and Tammela, \{T L J\} and S Vaage and O Lukkarinen and P Lodding and T Bull-Njaa and J Viitanen and P Hoisaeter and P Lundmo and F Rasmussen and J-E Johansson and B-E Persson and K Carroll and \{Scandinavian Prostatic Cancer Group (SPCG)\}",

year = "2002",

language = "English",

volume = "42",

pages = "204--11",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6

AU - Iversen, P

AU - Tammela, T L J

AU - Vaage, S

AU - Lukkarinen, O

AU - Lodding, P

AU - Bull-Njaa, T

AU - Viitanen, J

AU - Hoisaeter, P

AU - Lundmo, P

AU - Rasmussen, F

AU - Johansson, J-E

AU - Persson, B-E

AU - Carroll, K

AU - Scandinavian Prostatic Cancer Group (SPCG)

PY - 2002

Y1 - 2002

N2 - To assess the efficacy and tolerability of bicalutamide 150 mg ('Casodex'(1)) as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with early (T1b-T4, any N, M0) prostate cancer.

AB - To assess the efficacy and tolerability of bicalutamide 150 mg ('Casodex'(1)) as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with early (T1b-T4, any N, M0) prostate cancer.

KW - Aged

KW - Aged, 80 and over

KW - Anilides

KW - Antineoplastic Agents

KW - Chemotherapy, Adjuvant

KW - Combined Modality Therapy

KW - Double-Blind Method

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Nitriles

KW - Prostatic Neoplasms

KW - Sexual Behavior

KW - Survival Analysis

KW - Time Factors

KW - Tosyl Compounds

UR - https://www.scopus.com/pages/publications/0036715464

M3 - Journal article

C2 - 12234503

SN - 0302-2838

VL - 42

SP - 204

EP - 211

JO - European Urology

JF - European Urology

IS - 3

ER -